394 related articles for article (PubMed ID: 30611869)
21. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
Flahou C; Morishima T; Takizawa H; Sugimoto N
Front Immunol; 2021; 12():662360. PubMed ID: 33897711
[TBL] [Abstract][Full Text] [Related]
22. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
Woan KV; Kim H; Bjordahl R; Davis ZB; Gaidarova S; Goulding J; Hancock B; Mahmood S; Abujarour R; Wang H; Tuininga K; Zhang B; Wu CY; Kodal B; Khaw M; Bendzick L; Rogers P; Ge MQ; Bonello G; Meza M; Felices M; Huffman J; Dailey T; Lee TT; Walcheck B; Malmberg KJ; Blazar BR; Bryceson YT; Valamehr B; Miller JS; Cichocki F
Cell Stem Cell; 2021 Dec; 28(12):2062-2075.e5. PubMed ID: 34525347
[TBL] [Abstract][Full Text] [Related]
23. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.
Wang Z; Wang Z; Li B; Wang S; Chen T; Ye Z
Front Immunol; 2019; 10():1114. PubMed ID: 31156651
[TBL] [Abstract][Full Text] [Related]
24. Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.
Knorr DA; Bock A; Brentjens RJ; Kaufman DS
Stem Cells Dev; 2013 Jul; 22(13):1861-9. PubMed ID: 23421330
[TBL] [Abstract][Full Text] [Related]
25. Role of MicroRNAs in the development and function of innate immune cells.
Kumar Kingsley SM; Vishnu Bhat B
Int Rev Immunol; 2017 May; 36(3):154-175. PubMed ID: 28471289
[TBL] [Abstract][Full Text] [Related]
26. Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.
Jin G; Chang Y; Harris JD; Bao X
Cells Tissues Organs; 2023; 212(5):439-467. PubMed ID: 36599319
[TBL] [Abstract][Full Text] [Related]
27. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
Kaufman DS
Blood; 2009 Oct; 114(17):3513-23. PubMed ID: 19652198
[TBL] [Abstract][Full Text] [Related]
28. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
29. Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.
Zeng J; Tang SY; Toh LL; Wang S
Stem Cell Reports; 2017 Dec; 9(6):1796-1812. PubMed ID: 29173894
[TBL] [Abstract][Full Text] [Related]
30. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity.
Woll PS; Martin CH; Miller JS; Kaufman DS
J Immunol; 2005 Oct; 175(8):5095-103. PubMed ID: 16210613
[TBL] [Abstract][Full Text] [Related]
31. From pluripotent stem cells to T cells.
Montel-Hagen A; Crooks GM
Exp Hematol; 2019 Mar; 71():24-31. PubMed ID: 30590093
[TBL] [Abstract][Full Text] [Related]
32. Human innate lymphoid cells.
Montaldo E; Vacca P; Vitale C; Moretta F; Locatelli F; Mingari MC; Moretta L
Immunol Lett; 2016 Nov; 179():2-8. PubMed ID: 26844414
[TBL] [Abstract][Full Text] [Related]
33. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
[TBL] [Abstract][Full Text] [Related]
34. Directed Differentiation of Human Pluripotent Stem Cells to Microglia.
Douvaras P; Sun B; Wang M; Kruglikov I; Lallos G; Zimmer M; Terrenoire C; Zhang B; Gandy S; Schadt E; Freytes DO; Noggle S; Fossati V
Stem Cell Reports; 2017 Jun; 8(6):1516-1524. PubMed ID: 28528700
[TBL] [Abstract][Full Text] [Related]
35. Temporal Expression of Transcription Factor
Jung J; Chang Y; Jin G; Lian X; Bao X
ACS Synth Biol; 2022 Jun; 11(6):2001-2008. PubMed ID: 35608547
[TBL] [Abstract][Full Text] [Related]
36. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
Kanie K; Kaneko S
Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
[TBL] [Abstract][Full Text] [Related]
37. Characterization of human natural killer cells for therapeutic use.
Wagner AK; Alici E; Lowdell MW
Cytotherapy; 2019 Mar; 21(3):315-326. PubMed ID: 30910383
[TBL] [Abstract][Full Text] [Related]
38. Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.
Qin Y; Hutson C; Wu X; Xu J; Carroll D
Enliven J Stem Cell Res Regen Med; 2016 Mar; 3(1):. PubMed ID: 28845462
[TBL] [Abstract][Full Text] [Related]
39. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
40. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
